drugset / Trial / NCT06950086
Study of TYK-00540 Tablets in Patients With Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This study is to evaluate the safety, pharmacokinetics, and preliminary antitumor activity of TYK-00540 as monotherapy or combined with fulvestrant in advanced solid tumors.
Timeline
- Start
- 2024-01-02
- Primary completion
- 2026-09
- Completion
- 2026-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TYK-00540 | Unknown | 5 mg | Oral |
| Subject | TYK-00540 | Unknown | 10 mg | Oral |
| Subject | TYK-00540 | Unknown | 20 mg | Oral |
| Subject | TYK-00540 | Unknown | 30 mg | Oral |
| Subject | TYK-00540 | Unknown | 40 mg | Oral |